SCHEMBL6779529

SCHEMBL6779529

Nc1ccc2ccccc2c1CCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
GAA P10253 2/20 0.50
HSD17B10 Q99714 2/20 0.50
GLA P06280 1/20 0.50
HPGD P15428 1/20 0.50
CYP1A2 P05177 4/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2D6 P10635 2/20 0.49
EGFR P00533 2/20 0.44
SRC P12931 1/20 0.44
KEAP1 Q14145 1/20 0.44
FFAR1 O14842 2/20 0.43
AKR1B1 P15121 1/20 0.43
MAPT P10636 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29607264 1.00 KDM4E (0.50) KDM4EALDH1A1GAAHSD17B10GLA
Hydrochloric Acid SCHEMBL29175076 0.98 KDM4E (0.49) KDM4EALDH1A1GAAHSD17B10GLA
SCHEMBL5188827 0.83 KDM4E (0.67) KDM4EALDH1A1GAAHSD17B10GLA
SCHEMBL6773955 0.81 EGFR (0.49) KDM4EALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL8890863 0.81 KDM4E (0.70) KDM4EALDH1A1GAAHSD17B10GLA
SCHEMBL2992806 0.81 KDM4E (0.56) KDM4EALDH1A1GAAHSD17B10GLA
Hydrochloric Acid SCHEMBL27506548 0.80 EGFR (0.48) KDM4EALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL2125547 0.80 ALDH1A1 (0.50) KDM4EALDH1A1GAAHSD17B10GLA
SCHEMBL20563159 0.80 MTNR1A (0.47) KDM4EALDH1A1GAAHSD17B10GLA
SCHEMBL1882693 0.79 MEN1 (0.53) KDM4EALDH1A1GAAHSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4203988-A2 PEPTIDE INHIBITORS OF NF KAPPA B AND USE THEREOF IN TREATMENT OF COVID-19 AND INFLAMMATORY DISEASES Bhatnagar, Rajendra, Sahai (US) 2023-07-05 EP claimed
EP-3197474-A2 INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS Bhatnagar, Rajendra, Sahai (US) 2017-08-02 EP claimed
WO-2016049580-A2 INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS BHATNAGAR RAJENDRA SAHAI (US) 2016-03-31 WO claimed
EP-4203988-A2 PEPTIDE INHIBITORS OF NF KAPPA B AND USE THEREOF IN TREATMENT OF COVID-19 AND INFLAMMATORY DISEASES Bhatnagar, Rajendra, Sahai (US) 2023-07-05 EP disclosed
EP-3197474-A2 INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS Bhatnagar, Rajendra, Sahai (US) 2017-08-02 EP disclosed
WO-2016049580-A2 INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS BHATNAGAR RAJENDRA SAHAI (US) 2016-03-31 WO disclosed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-1261611-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-12-04 EP disclosed
EP-1252178-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-10-30 EP disclosed
CN-1085980-C Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists SEARLE & CO (US) 2002-06-05 CN disclosed
EP-1196436-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-04-17 EP disclosed
WO-2001064678-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-07 WO disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
WO-2001040262-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-07 WO disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 WO disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
US-4537907-A 2-AMINO-3-NAPHTHYL PROPIONIC ACID UNIVERSITY OF ILLINOIS FOUNDATION (US) 1985-08-27 US disclosed